Regeneron Pharmaceuticals reported a strong second quarter with revenues of $3.68 billion, surpassing analyst estimates despite regulatory challenges. The FDA delayed decisions on high-dose Eylea applications due to manufacturing issues at a Catalent facility and issued a complete response letter for the lymphoma drug odronextamab. While FDA manufacturing problems postponed approvals, Regeneron remains cautiously optimistic about resolving these issues and obtaining favorable outcomes, buoyed by robust earnings and product sales.